 Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company developing enzyme therapeutics for rare metabolic diseases with limited treatment options. Aegleas pipeline consists of two clinical-stage therapeutics and one in the late-pre-clinical stage covering primarily metabolic enzyme-related indications including arginase 1 deficiency, the indication of its lead Phase 3 therapeutic, Pegzilarginase. 